At the time of writing, Pacira BioSciences Inc [PCRX] stock is trading at $12.94, down -3.07%. An important factor to consider is whether the stock is rising or falling in short-term value. The PCRX shares have gain 10.60% over the last week, with a monthly amount drifted -36.00%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Pacira BioSciences Inc [NASDAQ: PCRX] stock has seen the most recent analyst activity on August 13, 2024, when Truist downgraded its rating to a Sell and also revised its price target to $8 from $30. Previously, RBC Capital Mkts downgraded its rating to Sector Perform on August 12, 2024, and dropped its price target to $14. On August 12, 2024, downgrade downgraded it’s rating to Mkt Perform. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $11 on August 12, 2024. JP Morgan downgraded its rating to a Underweight and reduced its price target to $10 on August 12, 2024. Barclays downgraded its rating to Equal Weight for this stock on July 03, 2024, and downed its price target to $25.
For the past year, the stock price of Pacira BioSciences Inc fluctuated between $11.16 and $38.23. Currently, Wall Street analysts expect the stock to reach $43 within the next 12 months. Pacira BioSciences Inc [NASDAQ: PCRX] shares were valued at $12.94 at the most recent close of the market. An investor can expect a potential return of 232.3% based on the average PCRX price forecast.
Analyzing the PCRX fundamentals
According to Pacira BioSciences Inc [NASDAQ:PCRX], the company’s sales were 690.31M for trailing twelve months, which represents an 5.05% jump. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.07 and Total Capital is 0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.69 points at the first support level, and at 12.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.27, and for the 2nd resistance point, it is at 13.60.
Ratios To Look Out For
It is important to note that Pacira BioSciences Inc [NASDAQ:PCRX] has a current ratio of 6.82. On the other hand, the Quick Ratio is 5.70, and the Cash Ratio is 2.67. Considering the valuation of this stock, the price to sales ratio is 0.86, the price to book ratio is 0.68 and price to earnings (TTM) ratio is 10.06.
Transactions by insiders
Recent insider trading involved YANG MICHAEL J., Director, that happened on Aug 14 ’24 when 2000.0 shares were purchased. Chief Executive Officer, Lee Frank D. completed a deal on Aug 12 ’24 to buy 8264.0 shares. Meanwhile, Director Froimson Mark bought 1400.0 shares on Aug 12 ’24.
